In an in vitro study of B16 melanoma cells, the binding of LAG-3 to LSECtin suppressed IFN-γ production and weakened the specific immune response against tumors, an effect that could be reversed by LAG-3 blockade (26). Here, LAG3 is linked to melanoma.